Aliases & Classifications for Cholera

MalaCards integrated aliases for Cholera:

Name: Cholera 12 50 56 52 41 3 3 42 14 69
Cholera Due to Vibrio Cholerae 12
Cholera - Vibrio Cholerae 12
Vibrio Cholerae Infection 50

Characteristics:

Orphanet epidemiological data:

56
cholera
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),<1/1000000 (United States); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 56  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1498
ICD9CM 35 001 001.0 001.9
MeSH 42 D002771
Orphanet 56 ORPHA173
MESH via Orphanet 43 D002771
UMLS via Orphanet 70 C0008354
ICD10 via Orphanet 34 A00.0 A00.1 A00.9
UMLS 69 C0008354

Summaries for Cholera

MedlinePlus : 41 cholera is a bacterial infection that causes diarrhea. the cholera bacterium is usually found in water or food contaminated by feces (poop). cholera is rare in the us. you may get it if you travel to parts of the world with inadequate water treatment and poor sanitation, and lack of sewage treatment. outbreaks can also happen after disasters. the disease is not likely to spread directly from one person to another. often the infection is mild or without symptoms, but sometimes it can be severe. severe symptoms include profuse watery diarrhea, vomiting, and leg cramps. in severe cases, rapid loss of body fluids leads to dehydration and shock. without treatment, death can occur within hours. doctors diagnose cholera with a stool sample or rectal swab. treatment includes replacing fluid and salts and sometimes antibiotics. anyone who thinks they may have cholera should seek medical attention immediately. dehydration can be rapid so fluid replacement is essential. centers for disease control and prevention

MalaCards based summary : Cholera, also known as cholera due to vibrio cholerae, is related to pancreatic cholera and secretory diarrhea, and has symptoms including fever and pruritus. An important gene associated with Cholera is ARF1 (ADP Ribosylation Factor 1), and among its related pathways/superpathways are GPCR Pathway and Vesicle-mediated transport. The drugs Formaldehyde and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include small intestine, skin and eye.

Disease Ontology : 12 A primary bacterial infectious disease that is described as an acute, diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae, which is characterized by profuse watery diarrhea, vomiting, leg cramps, circulatory collapse and shock.

NIH Rare Diseases : 50 cholera is an infection of the small intestines that is caused by the bacterium vibrio cholera. the condition can range from mild to severe and many affected people may have no obvious signs or symptoms. approximately 5-10% of infected people will have severe disease with watery diarrhea and vomiting leading to rapid fluid loss, dehydration, and shock. if left untreated, this can cause acute renal failure, severe electrolyte imbalances, coma, or even death. people develop cholera when they eat food or drink water that is contaminated with vibrio cholera. the condition occurs most often in places that lack water treatment and have poor sanitation and inadequate hygiene. treatment aims to prevent dehydration and replace the fluids and salts that are lost through diarrhea. last updated: 4/7/2016

Wikipedia : 72 Cholera is an infection of the small intestine by some strains of the bacterium Vibrio cholerae.... more...

Related Diseases for Cholera

Diseases related to Cholera via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 100)
id Related Disease Score Top Affiliating Genes
1 pancreatic cholera 12.0
2 secretory diarrhea 11.2
3 gastroenteritis 11.1
4 vipoma 10.8
5 wdha syndrome 10.8
6 pancreatitis 10.2
7 diarrhea 10.2
8 intracranial chondrosarcoma 10.1 CD79A CFTR
9 pertussis 10.1
10 mucositis 10.1
11 puerperal pulmonary embolism 9.9 ADCY10 CD79A
12 shigellosis 9.9
13 dysentery 9.9
14 acute diarrhea 9.9
15 neuronitis 9.8
16 typhoid fever 9.8
17 glioma 9.8
18 cholecystitis 9.8
19 nasal cavity carcinoma in situ 9.8 CD79A CFTR VIP
20 cystic fibrosis 9.8
21 plague 9.8
22 pasteurellosis 9.8
23 neuroblastoma 9.8
24 acalculous cholecystitis 9.8
25 conjunctivitis 9.7
26 allergic conjunctivitis 9.7
27 fasciitis 9.7
28 malaria 9.7
29 necrotizing fasciitis 9.7
30 lymphoma 9.6
31 pancreatic cancer 9.6
32 cellulitis 9.6
33 influenza 9.6
34 retinitis 9.6
35 neuropathy 9.6
36 malignant glioma 9.6
37 chlamydia 9.6
38 erysipelas 9.6
39 pneumonia 9.6
40 bacteremia 9.6
41 diphtheria 9.6
42 trichinosis 9.6
43 h. pylori infection 9.5
44 infant botulism 9.5
45 nephrotic syndrome 9.5
46 myelitis 9.5
47 waterhouse-friderichsen syndrome 9.5
48 metabolic acidosis 9.5
49 vaccinia 9.5
50 lymphopenia 9.5

Graphical network of the top 20 diseases related to Cholera:



Diseases related to Cholera

Symptoms & Phenotypes for Cholera

UMLS symptoms related to Cholera:


fever, pruritus

Drugs & Therapeutics for Cholera

Drugs for Cholera (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Formaldehyde Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-00-0 712
2
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
3
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
4
Mycophenolic acid Approved Phase 4 24280-93-1 446541
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
7 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
8 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1
9 Calcineurin Inhibitors Phase 4
10 Cholera Toxin Phase 4,Phase 3,Phase 1
11 Cyclosporins Phase 4
12 Immunosuppressive Agents Phase 4
13 Methylprednisolone acetate Phase 4
14 Methylprednisolone Hemisuccinate Phase 4
15 Prednisolone acetate Phase 4
16 Prednisolone hemisuccinate Phase 4
17 Prednisolone phosphate Phase 4
18
Azithromycin Approved Phase 3 83905-01-5 55185 53477736 447043
19
Ciprofloxacin Approved, Investigational Phase 3,Phase 1 85721-33-1 2764
20
Zinc Approved Phase 3,Phase 1,Phase 2 7440-66-6 32051 23994
21
Erythromycin Approved, Vet_approved Phase 3 114-07-8 12560
22 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
23 Anti-Infective Agents Phase 3,Phase 1,Phase 2
24 Cytochrome P-450 CYP1A2 Inhibitors Phase 3,Phase 1
25 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1
26 Topoisomerase Inhibitors Phase 3,Phase 1
27 Micronutrients Phase 3,Phase 1,Phase 2
28 Trace Elements Phase 3,Phase 1,Phase 2
29 Erythromycin Estolate Phase 3
30 Erythromycin Ethylsuccinate Phase 3
31 Erythromycin stearate Phase 3
32 Acidophilus Nutraceutical Phase 3
33
Albendazole Approved, Vet_approved Phase 1, Phase 2 54965-21-8 2082
34
Metronidazole Approved Phase 1, Phase 2 443-48-1 4173
35
Secnidazole Approved Phase 1, Phase 2 3366-95-8
36 Zinc sulfate Approved Phase 1, Phase 2 7733-02-0
37
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774
38
Vitamin C Approved, Nutraceutical Phase 2,Phase 1 50-81-7 5785 54670067
39
Butyric Acid Experimental Phase 2 107-92-6 264
40 Anthelmintics Phase 1, Phase 2
41 Antimitotic Agents Phase 1, Phase 2
42 Antiparasitic Agents Phase 1, Phase 2
43 Antiprotozoal Agents Phase 1, Phase 2
44 Astringents Phase 1, Phase 2
45 Dermatologic Agents Phase 1, Phase 2
46 Antibiotics, Antitubercular Phase 2
47 Histamine Antagonists Phase 2
48
Histamine Phosphate Phase 2 51-74-1 65513
49 Neurotransmitter Agents Phase 2
50 Guar Nutraceutical Phase 2

Interventional clinical trials:

(show top 50) (show all 75)

id Name Status NCT ID Phase Drugs
1 A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines Completed NCT01949675 Phase 4
2 Evaluation of a Boosting Regimen With Oral Cholera Vaccine Completed NCT01579448 Phase 4
3 A Study to Evaluate Safety and Immunogenicity of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Adults and Children Completed NCT00760825 Phase 4
4 Bridging Study for Killed Oral Cholera Vaccine in Ethiopia Completed NCT01524640 Phase 4
5 Mucosal Response in Immunocompromised Host Completed NCT01109914 Phase 4
6 Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever Completed NCT00125008 Phase 4
7 New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Diarrhea Management– Surveillance Study for Adverse Effects Completed NCT00490932 Phase 4 Hypo-osmolar ORS
8 VAXCHORA Pediatric Study Recruiting NCT03220737 Phase 4
9 Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh Unknown status NCT02027207 Phase 3
10 Randomized Controlled Field Trial of a Probiotics to Assess Its Role in Preventig Diarrhoea Unknown status NCT00534170 Phase 3
11 Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata Completed NCT00289224 Phase 3
12 A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic Completed NCT02434822 Phase 3
13 Ciprofloxacin Multiple Dose for Adult Cholera Completed NCT00741052 Phase 3 Ciprofloxacin;Azithromycin
14 Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Completed NCT01895855 Phase 3
15 Zinc Supplementation in Cholera Patients Completed NCT00226616 Phase 3 Zinc
16 Single Dose Azithromycin in the Treatment of Adult Cholera Completed NCT00229944 Phase 3 Azithromycin
17 Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial Completed NCT00142272 Phase 3 Ciprofloxacin
18 A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults Completed NCT02100631 Phase 3
19 A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults Completed NCT02094586 Phase 3
20 Oral Rehydration SolutionContaining Amylase Resistant Starch in Severely Malnourished Children. Completed NCT00324285 Phase 3 Amylase resistant starch added ORS
21 To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children Completed NCT02164110 Phase 3
22 Efficacy of an Oral, Killed Enterotoxigenic Escherichia Coli Vaccine in Prevention of Diarrhea in Egyptian Infants and Young Children Completed NCT02556996 Phase 3
23 Improving Rotavirus Vaccine Immune Response Completed NCT01825109 Phase 3
24 A Clinical Trial to Study the Effect and Safety of Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants Completed NCT02133690 Phase 3
25 Safety and Immunogenicity of a New Formulation of Euvichol® Not yet recruiting NCT02502331 Phase 3
26 Safety and Immunogenicity of a Killed Oral Cholera Vaccine in Infants Unknown status NCT00548054 Phase 2
27 Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata Completed NCT00119197 Phase 2
28 Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine Completed NCT00419133 Phase 2
29 Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine Completed NCT00128011 Phase 2
30 Study of Alternative Vaccination Schedule of Oral Cholera Vaccine Completed NCT01233362 Phase 2
31 To Determine the Safety and Immunogenicity of an Oral Whole Cell ShanChol Cholera Vaccine in Bangladesh Completed NCT01042951 Phase 2
32 Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine Completed NCT02742558 Phase 2
33 Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults Completed NCT00672308 Phase 2
34 Studies of Immune Responses to Orally Administered Vaccines in Developing Country Completed NCT01019083 Phase 1, Phase 2 Placebo;Placebo;Zinc Sulphate;Albendazole and Secnidazole
35 PXVX0200 (CVD103-HgR) vs Shanchol in Mali Completed NCT02145377 Phase 2
36 Field Application of Shanchol in Adults in Bangladesh Completed NCT01762930 Phase 2 Shanchol
37 Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults Completed NCT00741637 Phase 2
38 Slow Versus Rapid Rehydration of Severely Malnourished Children Completed NCT02216708 Phase 2
39 Therapeutic Induction of Endogenous Antibiotics Completed NCT00800930 Phase 2
40 Modified ORS Solution for Severely Malnourished Children Completed NCT01821586 Phase 2
41 Immunologic Responses to a Live Attenuated Oral Cholera Vaccine Recruiting NCT03251495 Phase 2 Vaxchora
42 Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine Active, not recruiting NCT02823899 Phase 1, Phase 2
43 Vaccines and Dietary Oats in the Treatment of Ulcerative Colitis Terminated NCT00751933 Phase 2
44 Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants Terminated NCT00624975 Phase 2
45 Efficacy of iOWH032 in Dehydrating Cholera Withdrawn NCT02111304 Phase 2 iOWH032
46 Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 Completed NCT01585181 Phase 1
47 Safety of An Oral O1 / O139 Cholera Vaccine (Enteric Capsules) Completed NCT03237663 Phase 1
48 To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men Completed NCT01707537 Phase 1
49 PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera Completed NCT01823939 Phase 1 iOWH032
50 Cholera Toxin B Subunit (CTB) Administered by Mucosal Way in Healthy Adult Volunteer Completed NCT00820144 Phase 1

Search NIH Clinical Center for Cholera

Cochrane evidence based reviews: cholera

Genetic Tests for Cholera

Anatomical Context for Cholera

MalaCards organs/tissues related to Cholera:

39
Small Intestine, Skin, Eye, T Cells, B Cells, Testes, Monocytes

Publications for Cholera

Articles related to Cholera:

(show top 50) (show all 949)
id Title Authors Year
1
Global stability and uniform persistence of the reaction-convection-diffusion cholera epidemic model. ( 27879114 )
2017
2
Zinc oxide nanoparticles provide anti-cholera activity by disrupting the interaction of cholera toxin with the human GM1 receptor. ( 28882894 )
2017
3
Cholera - the new strike of an old foe. ( 28952662 )
2017
4
Otitis Media Caused by V. cholerae O100: A Case Report and Review of the Literature. ( 28894440 )
2017
5
Affinity capillary electrophoresis for the assessment of binding affinity of carbohydrate-based cholera toxin inhibitors. ( 28905402 )
2017
6
Cholera, 2016. ( 28884993 )
2017
7
Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines. ( 28910563 )
2017
8
Descriptive epidemiology of a cholera outbreak in Kaduna State, Northwest Nigeria, 2014. ( 28904700 )
2017
9
Comparison of two control groups for estimation of oral cholera vaccine effectiveness using a case-control study design. ( 28916247 )
2017
10
Health seeking behaviour among suspected cases of cholera in Cameroonian health districts in Lake Chad basin. ( 28854951 )
2017
11
Development and standardization of an in-house indirect ELISA for detection of duck antibody to fowl cholera. ( 28844720 )
2017
12
Cost-of-illness of cholera to households and health facilities in rural Malawi. ( 28934285 )
2017
13
Sleep-inducing effect of substance P-cholera toxin A subunit in mice. ( 28866052 )
2017
14
Immunochromatographic detection of the heat-labile enterotoxin of enterotoxigenic Escherichia coli with cross-detection of cholera toxin. ( 27940044 )
2017
15
Induction of immunomodulatory miR-146a and miR-155 in small intestinal epithelium of Vibrio cholerae infected patients at acute stage of cholera. ( 28319200 )
2017
16
Ensuring access to oral cholera vaccine to those who need them most. ( 27916414 )
2017
17
The role of CTX and RS1 satellite phages genomic arrangement in Vibrio cholera toxin production in two recent cholera outbreaks (2012 and 2013) in IR Iran. ( 28923607 )
2017
18
IncA/C plasmids conferring high azithromycin resistance in vibrio cholera. ( 28919196 )
2017
19
Cholera vaccines: WHO position paper a89 August 2017. ( 28845659 )
2017
20
Cholera Vaccine Use Is Associated with a Reduced Risk of Death in Patients with Colorectal Cancer: A Population-based Study. ( 28923497 )
2017
21
Hetero-multivalent binding of cholera toxin subunit B with glycolipid mixtures. ( 28946063 )
2017
22
Eliminating Cholera Transmission in Haiti. ( 27959699 )
2017
23
Epistemological rehabilitation of "shoe leather" epidemiology: the lesson of cholera in Haiti. ( 28861644 )
2017
24
Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country. ( 27916412 )
2017
25
H2S is a key antisecretory molecule against cholera toxin-induced diarrhoea in mice: Evidence for non-involvement of the AC/cAMP/PKA pathway and AMPK. ( 28943473 )
2017
26
Passive, health center-based assessment of adverse events following oral cholera immunization in Nampula city, Mozambique. ( 28899627 )
2017
27
Oral Cholera Vaccine Coverage during an Outbreak and Humanitarian Crisis, Iraq, 2015. ( 27983502 )
2017
28
Deficiency in Calcium-Binding Protein S100A4 Impairs the Adjuvant Action of Cholera Toxin. ( 28951732 )
2017
29
Intestinal ameliorative effects of traditional Ogi-tutu, Vernonia amygdalina and Psidium guajava in mice infected with Vibrio cholera. ( 27605980 )
2016
30
Love of Angiotensin-Converting Enzyme Inhibitors in the Time of Cholera. ( 27107555 )
2016
31
High-Resolution Crystal Structures Elucidate the Molecular Basis of Cholera Blood Group Dependence. ( 27082955 )
2016
32
Origins of the current seventh cholera pandemic. ( 27849586 )
2016
33
Selective suppression by the medical establishment of unwelcome research findings: the cholera treatment evaluation by the General Board of Health, London 1854. ( 27150713 )
2016
34
The replication initiator of the cholera pathogen's second chromosome shows structural similarity to plasmid initiators. ( 28031373 )
2016
35
Injecting epidemiology into population viability analysis: avian cholera transmission dynamics at an arctic seabird colony. ( 27548394 )
2016
36
Potential for Controlling Cholera Using a Ring Vaccination Strategy: Re-analysis of Data from a Cluster-Randomized Clinical Trial. ( 27622507 )
2016
37
AA rare case of necrotizing fasciitis caused by Vibrio cholerae O8 in an immunocompetent patient. ( 27604649 )
2016
38
Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus. ( 27110810 )
2016
39
Modeling the within-host dynamics of cholera: bacterial-viral interaction. ( 28004608 )
2016
40
Clinical Features of Human Immunodeficiency Virus-Infected Patients Presenting with Cholera in Port-au-Prince, Haiti. ( 27549637 )
2016
41
A cholera outbreak investigation in Alborz province, Iran: matched case-control study. ( 27188308 )
2016
42
Antigen-independent restriction of pneumococcal density by mucosal adjuvant Cholera Toxin subunit B. ( 27112503 )
2016
43
Phenotypic and Genetic Heterogeneity in Vibrio cholerae O139 Isolated from Cholera Cases in Delhi, India during 2001-2006. ( 27555841 )
2016
44
Cholera in Cameroon, 2000-2012: Spatial and Temporal Analysis at the Operational (Health District) and Sub Climate Levels. ( 27855171 )
2016
45
Coalition for Cholera Prevention and Control. ( 27160041 )
2016
46
Cholera Rapid Test with Enrichment Step Has Diagnostic Performance Equivalent to Culture. ( 27992488 )
2016
47
Glycolipid Crosslinking Is Required for Cholera Toxin to Partition Into and Stabilize Ordered Domains. ( 27914621 )
2016
48
Oral immunisation of mice with transgenic rice calli expressing cholera toxin B subunit fused to consensus dengue cEDIII antigen induces antibodies to all four dengue serotypes. ( 27566485 )
2016
49
Blood Group O-Dependent Cellular Responses to Cholera Toxin: Parallel Clinical and Epidemiological Links to Severe Cholera. ( 27162272 )
2016
50
A single-dose antihelminthic treatment does not influence immunogenicity of a meningococcal and a cholera vaccine in Gabonese school children. ( 27642131 )
2016

Variations for Cholera

Expression for Cholera

Search GEO for disease gene expression data for Cholera.

Pathways for Cholera

Pathways related to Cholera according to GeneCards Suite gene sharing:

(show all 46)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.51 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
2
Show member pathways
13.24 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
3
Show member pathways
13.06 ADCY1 CFTR EGF GNAI1 GNAS PLCB1
4
Show member pathways
13.02 ADCY1 CD79A EGF GNAI1 GNAS PLCB1
5
Show member pathways
12.72 ADCY1 ADCY10 GNAI1 GNAS PLCB1
6
Show member pathways
12.65 ARF1 ARF3 ARF4 ARF5 ARL1
7 12.62 ADCY1 EGF GNAI1 GNAS PLCB1
8
Show member pathways
12.61 ADCY1 EGF GNAI1 GNAS PLCB1
9
Show member pathways
12.57 ADCY1 ARF6 EGF GNAI1 GNAS PLCB1
10
Show member pathways
12.51 ADCY1 GNAI1 GNAS PLCB1
11
Show member pathways
12.5 ADCY1 GNAI1 GNAS PLCB1
12
Show member pathways
12.44 ARF1 CFTR ERO1A GNAS
13 12.39 ARF1 ARF3 ARF5 ARF6
14
Show member pathways
12.33 ADCY1 GNAI1 GNAS PLCB1
15
Show member pathways
12.32 ADCY1 GNAI1 GNAS PLCB1
16 12.32 ADCY1 GNAI1 GNAS PLCB1
17
Show member pathways
12.27 ADCY1 EGF GNAI1 GNAS PLCB1
18
Show member pathways
12.13 ADCY1 GNAI1 GNAS PLCB1
19
Show member pathways
12.12 ADCY1 ARF1 ARF6 EGF GNAS PLCB1
20
Show member pathways
12.11 ADCY1 CFTR GNAI1 GNAS
21
Show member pathways
12.07 ADCY1 ADCY10 CFTR GNAI1 GNAS
22 12.02 ADCY1 GNAI1 GNAS VIP
23 11.96 ADCY1 ADCY10 GNAI1 PLCB1
24
Show member pathways
11.94 ADCY1 CFTR GNAI1 GNAS PLCB1
25 11.92 GNAI1 GNAS PLCB1
26
Show member pathways
11.91 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
27 11.89 ADCY1 GNAI1 GNAS PLCB1
28 11.85 ADCY1 EGF GNAI1 PLCB1
29 11.84 ADCY1 GNAS PLCB1
30 11.8 ADCY1 GNAI1 GNAS
31 11.72 ADCY1 CFTR GNAS PLCB1
32 11.67 ADCY1 CFTR GNAS
33 11.65 GNAI1 GNAS PLCB1
34 11.63 GNAI1 GNAS PLCB1
35 11.58 GNAI1 GNAS PLCB1
36 11.52 ADCY1 GNAI1 GNAS
37 11.49 GNAI1 GNAS PLCB1
38 11.46 ADCY1 GNAI1 GNAS
39 11.41 ADCY1 GNAS PLCB1
40 11.34 ARF1 ARF5 ARF6
41 11.28 ADCY1 GNAS PLCB1
42 11.23 GNAI1 GNAS PLCB1
43 10.99 ADCY10 GNAI1 GNAS PLCB1
44 10.86 ARF1 ARF6
45 10.79 GNAI1 PLCB1
46 10.7 ADCY1 GNAI1 GNAS PLCB1

GO Terms for Cholera

Cellular components related to Cholera according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 Golgi apparatus GO:0005794 9.87 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
2 intracellular GO:0005622 9.61 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
3 lysosomal membrane GO:0005765 9.55 CFTR EGF GNAI1 NEU1 TRIM23
4 extracellular exosome GO:0070062 9.5 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
5 membrane GO:0016020 10.16 ADCY1 ADCY10 ARF1 ARF4 ARF5 ARF6

Biological processes related to Cholera according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 vesicle-mediated transport GO:0016192 9.55 ARF1 ARF3 ARF4 ARF5 ARF6
2 retrograde vesicle-mediated transport, Golgi to ER GO:0006890 9.5 ARF3 ARF4 ARF5
3 cyclic nucleotide biosynthetic process GO:0009190 9.4 ADCY1 ADCY10
4 cAMP biosynthetic process GO:0006171 9.37 ADCY1 ADCY10
5 activation of phospholipase D activity GO:0031584 9.26 ARF4 ARL1
6 small GTPase mediated signal transduction GO:0007264 9.17 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
7 cellular response to forskolin GO:1904322 9.13 ADCY1 CFTR GNAI1

Molecular functions related to Cholera according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 GTP binding GO:0005525 9.61 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
2 G-protein beta/gamma-subunit complex binding GO:0031683 9.4 GNAI1 GNAS
3 phosphorus-oxygen lyase activity GO:0016849 9.37 ADCY1 ADCY10
4 GDP binding GO:0019003 9.33 ARF1 GNAI1 TRIM23
5 adenylate cyclase activity GO:0004016 9.32 ADCY1 ADCY10
6 GTPase activity GO:0003924 9.28 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
7 guanyl nucleotide binding GO:0019001 9.26 GNAI1 GNAS

Sources for Cholera

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....